Condition
Hemangioma Liver
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Completed2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03633747Phase 1TerminatedPrimary
Efficacy Evaluation of Propranolol Treatment of Hepatic Hemangioma
NCT04669314CompletedPrimary
Surgical Approach in Liver Hemangiomas
NCT03649113Phase 1CompletedPrimary
Percutaneous Sclerotherapy of Symptomatic Liver Hemangioma With Bleomycin
Showing all 3 trials